Menu
Back to Journals » Cancer Management and Research » Volume 13
RETRACTED ARTICLE: Silencing of LncRNA SNHG16 Downregulates Cyclin D1 (CCND1) to Abrogate Malignant Phenotypes in Oral Squamous Cell Carcinoma (OSCC) Through Upregulating miR-17-5p
Authors Wang Q, Han J, Xu P, Jian X, Huang X, Liu D
Received 22 December 2020
Accepted for publication 26 January 2021
Published 22 February 2021 Volume 2021:13 Pages 1831—1841
DOI https://doi.org/10.2147/CMAR.S298236
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
This paper has been retracted.
Wang Q, Han J, Xu P, Jian X, Huang X, Liu D. Cancer Manag Res. 2021;13:1831—1841.
We, the Editors and Publisher of the journal Cancer Management and Research, are retracting the published article.
Since publication, concerns have been raised by a third party regarding the integrity of the data in this article. Subsequently, the authors informed the Editor about the significant concerns regarding the reliability of the data presented in the article and so, have requested the retraction of the article.
As the Editor and Publisher also have concerns about the integrity of the reported results, all parties have agreed to retract the article to ensure correction of the scholarly record.
We have been informed in our decision-making by our editorial policies and the COPE guidelines.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms.php
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.